The American Academy of Dermatology (AAD) and Hidradenitis Suppurativa Foundation (HSF) have issued their first joint ...

Angela Fitch, MD, co-founder and chief medical officer of Knownwell, discussed GLP-1 access strategies and a proposed ...

In "How Emerging Oral Therapies Target HS Inflammation," the panel explores how JAK and BTK inhibitors interrupt inflammation ...

This episode, "Efficacy and Safety Data for Emerging Oral HS Agents," has Chao presenting the latest trial results for ...

Clinicians at a Dermatology Times Case-Based Roundtable, moderated by Chesahna Kindred, MD, debated when to escalate to oral JAK inhibitors for alopecia areata and how to counsel patients on timing, ...

Skin longevity is on a path to becoming a legitimate and consequential area of dermatology. For it to fully succeed, skin ...

Persistence and adherence, not efficacy claims alone, distinguish IL-23 biologics in practice. Real-world claims data reveal ...

At Fall Clinical 2026, Joel Gelfand, MD, MSCE, reviewed GLP-1 candidacy, weight conversations, and an upcoming monotherapy ...

Angela Fitch, MD, co-founder and chief medical officer of Knownwell and past president of the Obesity Medicine Association, ...

In "Access, Adherence, and Dosing Frequency in Older Psoriasis Patients," moderator and panelist weigh how injection ...

Christopher Bunick, MD, PhD, reviews data on investigational atopic dermatitis agents presented at EADV 2026 and biomarker ...

Remibrutinib is approved for chronic spontaneous urticaria (CSU) and most recently, symptomatic dermographism, with the label ...